Eli Lilly's Weight-Loss Drug Shows Promise; Cancer Deal Terminated

Thursday, October 1, 2026·Consolidated from 5 sources

Eli Lilly's investigational oral weight-loss drug, tirzepatide, met its primary endpoint in a Phase 3 trial, showing significant reductions in predicted long-term risk for type 2 diabetes and cardiovascular disease. However, the company has terminated a cancer drug deal with Foghorn Therapeutics, impacting the latter significantly.

Eli Lilly and Company announced positive results today for its investigational oral GLP-1 drug, tirzepatide, in a Phase 3 trial. Coverage today notes that the drug met its primary endpoint and was associated with significant reductions in the predicted long-term risk of developing type 2 diabetes and cardiovascular disease.

These findings suggest potential broad applications for tirzepatide beyond weight management, positioning it as a significant therapeutic candidate for multiple chronic conditions. The success in this trial comes amidst broader discussions in the market about the company's pipeline and existing portfolio.

In contrast to the positive drug development news, Eli Lilly has terminated a collaboration agreement concerning a cancer drug with Foghorn Therapeutics. Reports indicate that this decision has had a severe impact on Foghorn, leading to significant layoffs and a substantial drop in its stock value. Foghorn Therapeutics also provided an update on its strategic priorities and its FHD-909 drug candidate.

While the termination of the cancer deal represents a setback in that specific therapeutic area, the promising developments with tirzepatide underscore Eli Lilly's ongoing efforts to innovate across different disease states. The company continues to navigate its portfolio, balancing the progression of key assets with strategic decisions on partnerships and development programs.

Sources